Trial Profile
Analysis of third-line H. pylori eradication therapy with sitafloxacin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Sitafloxacin (Primary)
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- 04 May 2020 Status changed to discontinued.
- 09 May 2017 New trial record